TXLNA and pancreatic adenocarcinoma: The high TXLNA expression group had favourable OS in female PAAD patients (p=0.0047; HR: 0.3509; 95% CI: 0.1698–0.7248; Figure 3(a)), but not in male PAAD patients (p=0.5052; HR: 0.7952; 95% CI: 0.4053–1.5602; Figure 3(b)).